insights_auto
Why is ABVX up 2,37%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
79,85 €
arrow_upward
+2,37%(+1,85) 1D
27-окт., 17:35:11 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
77,50 €
High
80,30 €
Low
77,35 €
Mkt. cap
6,78 млд
Avg. vol.
123,21 миң
Volume
75,47 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
77,50 €
High
80,30 €
Low
77,35 €
Mkt. cap
6,78 млд
Avg. vol.
123,21 миң
Volume
75,47 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
ChartMill
·
24 мүнөт мурун
Top U.S. Gainers and Losers for Oct. 27, 2026 Session
Yahoo Finance
·
18 мүнөт мурун
Winners and losers of Q2: Sprout Social (NASDAQ:SPT) vs the rest of the sales and marketing software stocks
Hays Post
·
8 мүнөт мурун
Broadcom and other AI stocks lift Wall Street closer to another record
Reuters
·
1 саат мурун
NYSE moves to bring all-or-nothing options to stocks and company earnings
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com